Treating renal anaemia with recombinant human erythropoietin: practical guidelines and a clinical algorithm.
- 10 March 1990
- Vol. 300 (6725), 655-659
- https://doi.org/10.1136/bmj.300.6725.655
Abstract
Treatment with erythropoietin is highly effective and beneficial if given with care. In view of its cost, however, it is essential to exclude and treat other causes of anaemia before considering using this hormone. After treatment is started the important points for success are regular review of iron availability state combined with a slow correction of the anaemia. Failure of response requires a thorough search for a possible cause, which should be corrected before considering an increased dose of the hormone. Regular monitoring for potential complications, particularly a rise in blood pressure, is required.Keywords
This publication has 38 references indexed in Scilit:
- Treatment of the Anemia of Progressive Renal Failure with Recombinant Human ErythropoietinNew England Journal of Medicine, 1989
- Erythropoietin Treatment: Influence of Haemoglobin Concentration on Dialyser Creatinine Clearance in Haemodialysed PatientsNephron, 1989
- INTRAPERITONEAL ERYTHROPOIETINThe Lancet, 1988
- Blood Rheology and Hypertension in Hemodialysis Patients Treated with ErythropoietinAmerican Journal of Nephrology, 1988
- Correction of the Anemia of End-Stage Renal Disease with Recombinant Human ErythropoietinNew England Journal of Medicine, 1987
- PROSPECTIVE EVALUATION OF A MONOCLONAL ANTIBODY IN DIAGNOSIS OF PNEUMOCYSTIS CARINII PNEUMONIAThe Lancet, 1986
- Hemodialysis and continuous ambulatory peritoneal dialysis effects on erythropoiesis in renal failureKidney International, 1984
- Influence of continuous ambulatory peritoneal dialysis on the anemia of endstage renal diseaseKidney International, 1983
- Effect of parathyroid hormone on erythropoiesis.Journal of Clinical Investigation, 1981
- The diagnosis of iron deficiency anemiaAmerican Journal Of Medicine, 1964